Literature DB >> 23916805

On-pump versus off-pump coronary artery bypass surgery: cost-effectiveness analysis alongside a multisite trial.

Todd H Wagner1, Brack Hattler, Muath Bishawi, Janet H Baltz, Joseph F Collins, Jacquelyn A Quin, Frederick L Grover, A Laurie W Shroyer.   

Abstract

BACKGROUND: Questions have been raised about the costs and outcomes for patients receiving on-pump and off-pump coronary artery bypass graft surgery. As part of the Department of Veterans Affairs Randomized On/Off Bypass (ROOBY) multisite trial, a cost-effectiveness analysis was performed to compare on-pump versus off-pump patients' quality-adjusted life-years and costs at 1 year.
METHODS: One-year outcomes and costs (standardized to 2010 dollars) were estimated in multivariate regression models, controlling for site and baseline patient factors. The 1-year incremental cost-effectiveness analysis ratio with 95% confidence intervals was calculated using bootstrapping.
RESULTS: Eighteen centers randomly assigned 2,203 participants to on-pump (n=1,099) versus off-pump (n=1,104) coronary artery bypass graft surgery. Both groups' quality of life improved significantly after surgery (p<0.01) compared with baseline, but no differences were found between treatment groups. Adjusted cost of the index coronary artery bypass graft surgery hospitalization was $36,046 on-pump and $36,536 off-pump (p=0.16). At 1 year, on-pump adjusted cost was $56,023 versus $59,623 off-pump (p=0.046). Off-pump-to-on-pump conversions after first distal anastomosis (4.8%) had significantly higher 1-year costs. Excluding conversions, there were no significant differences between treatments for index hospitalization or 1-year total costs.
CONCLUSIONS: At 1 year, off-pump coronary artery bypass graft surgery was more expensive than on-pump when late off-pump-to-on-pump conversions were included. Excluding late conversions, there was no difference in quality-adjusted life-years or costs. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00032630; http://clinicaltrials.gov/ct2/show/NCT00032630.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  23

Mesh:

Year:  2013        PMID: 23916805     DOI: 10.1016/j.athoracsur.2013.04.074

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Costs of Endoscopic vs Open Vein Harvesting for Coronary Artery Bypass Grafting: A Secondary Analysis of the REGROUP Trial.

Authors:  Todd H Wagner; Brack Hattler; Eileen M Stock; Kousick Biswas; Deepak L Bhatt; Faisal G Bakaeen; Kritee Gujral; Marco A Zenati
Journal:  JAMA Netw Open       Date:  2022-06-01

Review 2.  Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.

Authors:  Andrea Gabrio; Alexina J Mason; Gianluca Baio
Journal:  Pharmacoecon Open       Date:  2017-06

Review 3.  Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies.

Authors:  Bart S Ferket; Jonathan M Oxman; Alexander Iribarne; Annetine C Gelijns; Alan J Moskowitz
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-15       Impact factor: 5.209

4.  Preoperative factors affecting cost and length of stay for isolated off-pump coronary artery bypass grafting: hierarchical linear model analysis.

Authors:  Daisuke Shinjo; Kiyohide Fushimi
Journal:  BMJ Open       Date:  2015-11-17       Impact factor: 2.692

Review 5.  Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate.

Authors:  Mario Gaudino; Gianni D Angelini; Charalambos Antoniades; Faisal Bakaeen; Umberto Benedetto; Antonio M Calafiore; Antonino Di Franco; Michele Di Mauro; Stephen E Fremes; Leonard N Girardi; David Glineur; Juan Grau; Guo-Wei He; Carlo Patrono; John D Puskas; Marc Ruel; Thomas A Schwann; Derrick Y Tam; James Tatoulis; Robert Tranbaugh; Michael Vallely; Marco A Zenati; Michael Mack; David P Taggart
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.